A MnO2 Nanoparticle-Dotted Hydrogel Promotes Spinal Cord Repair via Regulating Reactive Oxygen Species Microenvironment and Synergizing with Mesenchymal Stem Cells
Citations Over TimeTop 1% of 2019 papers
Abstract
Spinal cord injury (SCI) is one of the most debilitating injuries, and transplantation of stem cells in a scaffold is a promising strategy for treatment. However, stem cell treatment of SCI has been severely impaired by the increased generation of reactive oxygen species in the lesion microenvironment, which can lead to a high level of stem cell death and dysfunction. Herein, a MnO2 nanoparticle (NP)-dotted hydrogel is prepared through dispersion of MnO2 NPs in a PPFLMLLKGSTR peptide modified hyaluronic acid hydrogel. The peptide-modified hydrogel enables the adhesive growth of mesenchymal stem cells (MSCs) and nerve tissue bridging. The MnO2 NPs alleviate the oxidative environment, thereby effectively improving the viability of MSCs. Transplantation of MSCs in the multifunctional gel generates a significant motor function restoration on a long-span rat spinal cord transection model and induces an in vivo integration as well as neural differentiation of the implanted MSCs, leading to a highly efficient regeneration of central nervous spinal cord tissue. Therefore, the MnO2 NP-dotted hydrogel represents a promising strategy for stem-cell-based therapies of central nervous system diseases through the comprehensive regulation of pathological microenvironment complications.
Related Papers
- → The immunosuppressive capacity of human mesenchymal stromal cells derived from amnion and bone marrow(2016)34 cited
- → Mesenchymal stem cell therapy in treatment of erectile dysfunction: Autologous or allogeneic cell sources?(2014)32 cited
- → Mesenchymal Stem/Stromal Cells: ASSESSING THE SAFETY AND TOXICITY OF VERY HIGH DOSES OF ALLOGENEIC HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS(2023)1 cited
- → Mesenchymal Stem/Stromal Cells: THE EFFECTS OF ADIPOSE TISSUE MESENCHYMAL STEM CELLS (AT-MSCS) ON IMMUNOLOGICAL PATTERNS IN FEMALES WITH MULTIPLE SCLEROSIS(2022)
- → Mesenchymal Stem/Stromal Cells: COMMENCEMENT OF FIRST-IN-HUMAN FOR CLINICAL TRIAL OF ADIPOSE TISSUE DERIVED ALLOGENEIC MESENCHYMAL STEM CELL (ADMSC) SHEETS FOR RETINAL DISEASES(2023)